/

CGEN

Compugen Ltd.Closed

1.98−0.09 −4.35%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 2.01 +1.52%

Open

2.08

Prev close

2.07

Day range

1.962.09

52-week range

1.433.24

Volume

223.38K0.93×

Mkt cap

187.55M

P/E ttm

5.21

Fwd P/E

-5.40

EPS ttm

0.3800

Div yield

0.00%

Earnings

Aug 3, 2026

From 52w high

−38.89%

Price Chart

Yahoo Finance · delayed

CGENOct 12, 2026O 2.13H 2.13L 2.07C 2.07−0.06 (−2.82%)Vol 86.50K

SMA 502.44
SMA 2002.27

1Y change +11.89% since Oct 10, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

CGEN Compugen Ltd. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −10.39%
1 month: −16.19%
3 months: −10.00%
6 months: −25.00%
Year to date: +35.29%
1 year: +11.89%

Valuation & ownership

Market cap: 187.55M
Enterprise value: 65.28M
P/E (ttm): 5.21
Forward P/E: -5.40
PEG ratio: 1.29
Price / book: 2.11
Price / sales (ttm): 2.53
EV / EBITDA: 2.13
EPS (ttm): 0.3800
EPS (forward): -0.3667
Beta (5y monthly): 2.79
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 94.72M
Float: 94.51M
Short % of float: 2.49%
Short ratio (days): 13.67
Held by insiders: 0.20%
Held by institutions: 15.22%
Avg volume (3m): 241.30K
50-day average: 2.44
200-day average: 2.27
52-week change: +11.89%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 28.1
vs 50-day SMA: −15.02%
vs 200-day SMA: −8.94%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 4.28%
Realised vol (20d, ann.): 35.3%
From 52-week high: −36.11%
From 52-week low: +44.76%

ANR

Analyst Consensus

5 analysts

Consensus

Strong buy

1.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

4.60

+132.32% implied

Low 4.00Median 4.00High 6.00

Recommendation trend

Now5 / 0 / 0
1m ago5 / 0 / 0
2m ago

DES

About Compugen Ltd.

Yahoo Finance profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.

Sector: Healthcare
Industry: Biotechnology
Employees: 75
Headquarters: Holon, Israel
Website: cgen.com

SEAS

Seasonality · CGEN

2007–2026 · monthly returns

Strongest month Jan +14.85%Weakest month Nov −2.81%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	20.3	-1.6	17.7	24.9	-1.1	-18.6	9.8	8.9	-7.0	-16.8			+29.4%
2025	52.3	-17.6	-24.0	9.6	-8.1	21.1	-18.5	-2.8	4.3	20.4	-11.9	-1.9	0.0%
2024	21.7	7.1	0.0	-25.2	12.4	-22.6	5.4	18.6	-13.8	-11.6	-0.6	-3.8	−22.7%
2023	20.8	-9.2	-11.4	-15.7	72.9	11.8	1.8	-1.7	-18.4	-18.3	-13.2	200.0	+175.0%
2022	-17.4	-13.0	4.2	-26.1	-22.3	0.0	-13.0	-27.3	-43.6	43.9	26.3	-40.0	−83.3%
2021	0.4	-23.3	-7.9	0.5	-11.0	7.8	-18.0	3.4	-15.0	8.7	-31.9	-2.7	−64.5%
2020	20.8	26.0	-20.0	99.6	6.2	-2.4	-4.1	20.0	-6.0	-20.7	-0.4	-5.7	+103.2%
2019	59.0	-0.3	20.3	-15.5	-20.0	37.1	-15.6	18.8	9.9	21.3	18.7	-2.1	+174.7%
2018	20.0	33.3	11.2	-21.3	7.1	-12.0	-4.5	23.8	-1.3	-20.0	12.3	-37.3	−13.2%
2017	-6.9	-10.5	1.2	-5.8	18.5	-20.8	6.6	-24.7	24.6	-21.1	-18.3	2.0	−51.0%
2016	-26.3	0.8	17.5	21.5	2.7	-6.9	2.6	5.7	-10.4	-8.7	5.2	-15.7	−20.2%
2015	-6.8	7.7	-15.7	-9.1	10.5	-2.0	-11.5	-19.9	5.1	19.7	22.8	-15.9	−23.3%
2014	20.9	4.8	-7.3	-10.8	-13.6	11.0	-5.2	4.5	-3.7	-16.7	-2.4	19.5	−6.9%
2013	10.2	-0.6	-5.9	18.1	-2.5	-7.0	-2.6	83.6	5.7	-2.5	3.9	-13.9	+81.9%
2012	8.1	14.6	-2.3	-11.9	-33.1	9.3	-11.7	6.5	3.6	-2.4	25.1	7.2	−0.6%
2011	6.3	-2.9	1.2	-7.2	-8.8	-6.7	-0.2	-6.4	5.5	4.5	6.5	11.2	+0.6%
2010	-19.2	12.2	11.4	-2.4	-10.7	-22.0	26.4	-11.6	26.9	-2.1	-18.0	29.8	+1.4%
2009	30.2	-10.7	32.0	65.2	0.9	82.7	22.4	17.1	6.2	-16.3	9.4	73.2	+1027.9%
2008	71.9	-10.2	-15.4	10.0	-11.7	5.9	6.5	-10.5	-19.0	-12.0	-58.9	-28.3	−73.1%
2007	16.2	-18.3	8.1	9.0	0.0	0.3	1.7	-14.9	-1.2	-2.8	-28.1	-8.0	−38.2%

INSD

Insider Activity · CGEN

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

125.5K shares

Sells, 6 months

19K shares

Net shares

+106.5K

Net change in insider shares

+125.80%

Date	Insider	Transaction	Shares	Value
Jul 28, 2026	Zweifach Sanford SDirector	Stock Award(Grant) at price 0.00 per share.	7.5K	—
Jul 28, 2026	Levine ZuritOfficer	Stock Award(Grant) at price 0.00 per share.	18K	—
Jul 28, 2026	Silberman DavidChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	19.5K	—
Jul 28, 2026	Hukkelhoven Mathias Ph.D.Director	Stock Award(Grant) at price 0.00 per share.	7.5K	—
Jul 28, 2026	Halevy GileadDirector	Stock Award(Grant) at price 0.00 per share.	7.5K	—
Jul 8, 2026	Levine ZuritOfficer	Sale at price 2.50 per share.	1.9K	$4.69K
Jul 8, 2026	Levine ZuritOfficer	Conversion of Exercise of derivative security at price 0.83 per share.	1.9K	$1.55K
Apr 23, 2026	Levine ZuritOfficer	Sale at price 3.20 per share.	2K	$6.40K
Apr 23, 2026	Ophir EranChief Executive Officer	Sale at price 3.20 per share.	5K	$16.00K
Apr 23, 2026	Levine ZuritOfficer	Conversion of Exercise of derivative security at price 1.15 per share.	2K	$2.30K
Apr 23, 2026	Ophir EranChief Executive Officer	Conversion of Exercise of derivative security at price 0.83 per share.	5K	$4.15K
Apr 13, 2026	Levine ZuritOfficer	Sale at price 2.80 per share.	2K	$5.60K
Apr 13, 2026	Ophir EranChief Executive Officer	Sale at price 2.90 per share.	5K	$14.52K
Apr 13, 2026	Levine ZuritOfficer	Conversion of Exercise of derivative security at price 1.15 per share.	2K	$2.30K
Apr 13, 2026	Ophir EranChief Executive Officer	Conversion of Exercise of derivative security at price 0.83 per share.	5K	$4.15K
Apr 9, 2026	Levine ZuritOfficer	Sale at price 2.56 per share.	3.1K	$8.01K
Apr 9, 2026	Levine ZuritOfficer	Sale at price 2.56 per share.	3.1K	$8.01K
Apr 9, 2026	Levine ZuritOfficer	Conversion of Exercise of derivative security at price 0.83 - 1.15 per share.	3.1K	$3.23K
Apr 9, 2026	Levine ZuritOfficer	Conversion of Exercise of derivative security at price 0.83 - 1.15 per share.	3.1K	$3.23K
Apr 7, 2026	Levine ZuritOfficer	Sale at price 2.30 - 2.42 per share.	7.9K	$18.76K

13F

Investors Holding CGEN

latest 13F filings of 29 followed managers

Investors holding CGEN
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$4.0M	0.01%	1.88M	+15%	Q2 2026
ARK Investment Management · Cathie Wood	$1.7M	0.01%	786.54K	−25%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

CGEN

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

CGEN

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Compugen Ltd.

Seasonality · CGEN

Insider Activity · CGEN

Congress Trades · CGEN

Investors Holding CGEN

Investors Holding CGEN

Congress Trades · CGEN

Insider Activity · CGEN

Seasonality · CGEN

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Compugen Ltd.

Financial Snapshot

Earnings & Dividends

News